1
|
Ragan EJ, McCallum C, Marathe J, Cole M, Hofman M, Henderson AJ, Flack T, Miller NS, Burks EJ, Zhao GQ, Denis R, Lin NH, Jacobson KR, Andry CD, Pelton SI, Duffy ER, Bhadelia N. Pandemic Response Requires Research Samples: A U.S. Safety-Net Hospital's Experience and Call for National Action. Ann Intern Med 2021; 174:1727-1732. [PMID: 34724402 DOI: 10.7326/m21-2857] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Biorepositories provide a critical resource for gaining knowledge of emerging infectious diseases and offer a mechanism to rapidly respond to outbreaks; the emergence of the novel coronavirus, SARS-CoV-2, has proved their importance. During the COVID-19 pandemic, the absence of centralized, national biorepository efforts meant that the onus fell on individual institutions to establish sample repositories. As a safety-net hospital, Boston Medical Center (BMC) recognized the importance of creating a COVID-19 biorepository to both support critical science at BMC and ensure representation in research for its urban patient population, most of whom are from underserved communities. This article offers a realistic overview of the authors' experience in establishing this biorepository at the onset of the COVID-19 pandemic during the height of the first surge of cases in Boston, Massachusetts, with the hope that the challenges and solutions described are useful to other institutions. Going forward, funders, policymakers, and infectious disease and public health communities must support biorepository implementation as an essential element of future pandemic preparedness.
Collapse
Affiliation(s)
- Elizabeth J Ragan
- Section of Infectious Diseases and Research Operations, Boston Medical Center, Boston, Massachusetts (E.J.R.)
| | - Caitryn McCallum
- Section of Infectious Diseases, Boston Medical Center, and Center for Emerging Infectious Diseases Policy and Research, Boston University, Boston, Massachusetts (C.M.)
| | - Jai Marathe
- Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts (J.M., N.H.L., K.R.J.)
| | - Manisha Cole
- Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, Massachusetts (M.C., N.S.M., E.J.B., G.Q.Z.)
| | - Melissa Hofman
- Clinical Data Warehouse, Boston Medical Center, Boston, Massachusetts (M.H.)
| | - Andrew J Henderson
- Section of Infectious Diseases, Boston Medical Center, and Department of Microbiology, Boston University School of Medicine, Boston, Massachusetts (A.J.H.)
| | - Tyler Flack
- Research Operations, Boston Medical Center, Boston, Massachusetts (T.F.)
| | - Nancy S Miller
- Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, Massachusetts (M.C., N.S.M., E.J.B., G.Q.Z.)
| | - Eric J Burks
- Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, Massachusetts (M.C., N.S.M., E.J.B., G.Q.Z.)
| | - Grace Qing Zhao
- Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, Massachusetts (M.C., N.S.M., E.J.B., G.Q.Z.)
| | - Ridiane Denis
- General Clinical Research Unit, Boston University, Boston, Massachusetts (R.D.)
| | - Nina H Lin
- Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts (J.M., N.H.L., K.R.J.)
| | - Karen R Jacobson
- Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts (J.M., N.H.L., K.R.J.)
| | - Christopher D Andry
- Department of Pathology and Laboratory Medicine, Boston Medical Center, and Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts (C.D.A., E.R.D.)
| | - Stephen I Pelton
- Section of Pediatric Infectious Diseases, Department of Pediatrics, Boston University Medical Center, Department of Epidemiology, Boston University School of Public Health, and Maxwell Finland Laboratory for Infectious Diseases, Boston, Massachusetts (S.I.P.)
| | - Elizabeth R Duffy
- Department of Pathology and Laboratory Medicine, Boston Medical Center, and Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts (C.D.A., E.R.D.)
| | - Nahid Bhadelia
- Section of Infectious Diseases, Boston Medical Center, and Center for Emerging Infectious Diseases Policy and Research and National Emerging Infectious Diseases Laboratories, Boston University, Boston, Massachusetts (N.B.)
| |
Collapse
|
2
|
Selby R, Duffy ER, Berny-Lang MA, Andry CD, Lee AYY. Impact of specific preclinical variables on coagulation biomarkers in cancer-associated thrombosis. Thromb Res 2021; 191 Suppl 1:S26-S30. [PMID: 32736774 DOI: 10.1016/s0049-3848(20)30393-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2019] [Revised: 11/18/2019] [Accepted: 11/24/2019] [Indexed: 10/23/2022]
Abstract
Coagulation biomarkers are being actively studied for their diagnostic and prognostic value in patients with venous thromboembolism and cancer, as well as in the study of pathogenic mechanisms between cancer and thrombosis. For the results of such studies to be accurate and reproducible, attention must be paid to minimize sources of error in all phases of testing. The pre-analytical phase of laboratory testing is known to be fraught with the majority of errors. Coagulation testing is particularly susceptible to conditions during collection, processing, transport and storage of specimens which can lead to clinically significant errors in results. In addition, changes in pre-analytical conditions can impact different biomarkers differently. Therefore, research studies investigating coagulation biomarkers must carefully standardize not just the analytical phase, but also the pre-analytical phase of testing to ensure accuracy and reliability. We briefly review the impact of pre-analytical conditions on coagulation testing in general, and on specific biomarkers in cancer and thrombosis. In addition, we provide recommendations to reduce pre-analytical errors by developing and sharing standard operating procedures that specifically target standardization of methodologies for collecting specimens and measuring current and emerging coagulation biomarkers in cancer studies.
Collapse
Affiliation(s)
- Rita Selby
- Departments of Laboratory Medicine and Pathobiology & Medicine, University of Toronto, Toronto, ON, Canada
| | - Elizabeth R Duffy
- Department of Pathology & Laboratory Medicine, Boston University School of Medicine, Boston Medical Center, Boston, MA, USA
| | - Michelle A Berny-Lang
- Center for Strategic Scientific Initiatives, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Christopher D Andry
- Department of Pathology & Laboratory Medicine, Boston University School of Medicine, Boston Medical Center, Boston, MA, USA
| | - Agnes Y Y Lee
- University of British Columbia, British Columbia Cancer Agency, Vancouver, BC, Canada.
| |
Collapse
|
3
|
Vanuytsel K, Mithal A, Giadone RM, Yeung AK, Matte TM, Dowrey TW, Werder RB, Miller GJ, Miller NS, Andry CD, Murphy GJ. Rapid Implementation of a SARS-CoV-2 Diagnostic Quantitative Real-Time PCR Test with Emergency Use Authorization at a Large Academic Safety Net Hospital. Med 2020; 1:152-157.e3. [PMID: 32838351 PMCID: PMC7235561 DOI: 10.1016/j.medj.2020.05.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2020] [Revised: 04/24/2020] [Accepted: 05/01/2020] [Indexed: 01/16/2023]
Abstract
BACKGROUND Significant delays in the rapid development and distribution of diagnostic testing for SARS-CoV-2 (COVID-19) infection have prevented adequate public health management of the disease, impacting the timely mapping of viral spread and the conservation of personal protective equipment. Furthermore, vulnerable populations, such as those served by the Boston Medical Center (BMC), the largest safety net hospital in New England, represent a high-risk group across multiple dimensions, including a higher prevalence of pre-existing conditions and substance use disorders, lower health maintenance, unstable housing, and a propensity for rapid community spread, highlighting the urgent need for expedient and reliable in-house testing. METHODS We developed a SARS-CoV-2 diagnostic medium-throughput qRT-PCR assay with rapid turnaround time and utilized this Clinical Laboratory Improvement Amendments (CLIA)-certified assay for testing nasopharyngeal swab samples from BMC patients, with emergency authorization from the Food and Drug Administration (FDA) and the Massachusetts Department of Public Health. FINDINGS The in-house testing platform displayed robust accuracy and reliability in validation studies and reduced institutional sample turnaround time from 5-7 days to less than 24 h. Of over 1,000 unique patient samples tested, 44.1% were positive for SARS-CoV-2 infection. CONCLUSIONS This work provides a blueprint for academic centers and community hospitals lacking automated laboratory machinery to implement rapid in-house testing. FUNDING This study was supported by funding from the Boston University School of Medicine, the National Institutes of Health, Boston Medical Center, and the Massachusetts Consortium on Pathogen Readiness (MASS CPR).
Collapse
Affiliation(s)
- Kim Vanuytsel
- Center for Regenerative Medicine, Boston University and Boston Medical Center, Boston, MA 02218, USA
- Section of Hematology and Oncology, Department of Medicine, Boston University School of Medicine, Boston, MA 02218, USA
| | - Aditya Mithal
- Center for Regenerative Medicine, Boston University and Boston Medical Center, Boston, MA 02218, USA
| | - Richard M Giadone
- Center for Regenerative Medicine, Boston University and Boston Medical Center, Boston, MA 02218, USA
| | - Anthony K Yeung
- Center for Regenerative Medicine, Boston University and Boston Medical Center, Boston, MA 02218, USA
| | - Taylor M Matte
- Center for Regenerative Medicine, Boston University and Boston Medical Center, Boston, MA 02218, USA
| | - Todd W Dowrey
- Center for Regenerative Medicine, Boston University and Boston Medical Center, Boston, MA 02218, USA
| | - Rhiannon B Werder
- Center for Regenerative Medicine, Boston University and Boston Medical Center, Boston, MA 02218, USA
| | - Gregory J Miller
- Center for Regenerative Medicine, Boston University and Boston Medical Center, Boston, MA 02218, USA
| | - Nancy S Miller
- Department of Pathology and Laboratory Medicine, Boston Medical Center and Boston University School of Medicine, Boston, MA 02218, USA
| | - Christopher D Andry
- Department of Pathology and Laboratory Medicine, Boston Medical Center and Boston University School of Medicine, Boston, MA 02218, USA
| | - George J Murphy
- Center for Regenerative Medicine, Boston University and Boston Medical Center, Boston, MA 02218, USA
- Section of Hematology and Oncology, Department of Medicine, Boston University School of Medicine, Boston, MA 02218, USA
| |
Collapse
|
4
|
Giadone RM, Mithal A, Miller GJ, Matte TM, Yeung AK, Dowrey TW, Werder RB, Miller NS, Andry CD, Vanuytsel K, Murphy GJ. qRT-PCR Platforms for Diagnosing and Reporting SARS-CoV-2 Infection in Human Samples. STAR Protoc 2020; 1:100102. [PMID: 32954369 PMCID: PMC7490627 DOI: 10.1016/j.xpro.2020.100102] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
The protocols herein outline the use of qRT-PCR to detect the presence of SARS-CoV-2 genomic RNA in patient samples. In order to cope with potential fluctuations in supply chain and testing demands and to enable expedient adaptation of reagents and assays on hand, we include details for three parallel methodologies (one- and two-step singleplex and one-step multiplex assays). The diagnostic platforms described can be easily adapted by basic science research laboratories for SARS-CoV-2 diagnostic testing with relatively short turnaround time. For complete details on the use and execution of this protocol, please refer to Vanuytsel et al. (2020).
Collapse
Affiliation(s)
- Richard M. Giadone
- Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA
| | - Aditya Mithal
- Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA
| | - Gregory J. Miller
- Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA
| | - Taylor M. Matte
- Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA
| | - Anthony K. Yeung
- Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA
| | - Todd W. Dowrey
- Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA
| | - Rhiannon B. Werder
- Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA
| | - Nancy S. Miller
- Department of Pathology and Laboratory Medicine, Boston Medical Center and Boston University School of Medicine, Boston, MA 02218, USA
| | - Christopher D. Andry
- Department of Pathology and Laboratory Medicine, Boston Medical Center and Boston University School of Medicine, Boston, MA 02218, USA
| | - Kim Vanuytsel
- Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA
- Section of Hematology and Oncology, Department of Medicine, Boston University School of Medicine, Boston, MA 02218, USA
| | - George J. Murphy
- Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA
- Section of Hematology and Oncology, Department of Medicine, Boston University School of Medicine, Boston, MA 02218, USA
| |
Collapse
|
5
|
Richez C, Richards RJ, Duffau P, Weitzner Z, Andry CD, Rifkin IR, Aprahamian T. The effect of mycophenolate mofetil on disease development in the gld.apoE (-/-) mouse model of accelerated atherosclerosis and systemic lupus erythematosus. PLoS One 2013; 8:e61042. [PMID: 23577189 PMCID: PMC3620051 DOI: 10.1371/journal.pone.0061042] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2012] [Accepted: 03/05/2013] [Indexed: 01/01/2023] Open
Abstract
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that is characterized by autoantibody production and inflammatory disease involving multiple organs. Premature atherosclerosis is a common complication of SLE and results in substantial morbidity and mortality from cardiovascular disease (CVD). The reasons for the premature atherosclerosis in SLE are incompletely understood, although chronic inflammation is thought to play an important role. There is currently no known preventative treatment of premature atherosclerosis in SLE. Mycophenolate mofetil (MMF) is an immunosuppressive agent that is commonly used for treatment of patients with SLE. In order to study the impact of this drug on murine lupus disease including premature atherosclerosis development, we treated gld.apoE−/− mice, a model of SLE and accelerated atherosclerosis, with MMF. We maintained seven-week old gld.apoE−/− mice on a high cholesterol Western diet with or without MMF. After 12 weeks on diet, mice receiving MMF showed decreased atherosclerotic lesion area compared to the control group. MMF treatment also improved the lupus phenotype, indicated by a significant decrease circulating autoantibody levels and ameliorating lupus nephritis associated with this model. This data suggests that the effects of MMF on the immune system may not only be beneficial for lupus, but also for inflammation driving lupus-associated atherosclerosis.
Collapse
Affiliation(s)
- Christophe Richez
- Service de Rhumatologie, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France
- UMR-CNRS 5164, Université Victor Segalen Bordeaux 2, Bordeaux, France
- Department of Medicine-Renal Section, Boston University School of Medicine, Boston, Massachusetts, United States of America
| | - Rocco J. Richards
- Department of Medicine-Renal Section, Boston University School of Medicine, Boston, Massachusetts, United States of America
| | - Pierre Duffau
- UMR-CNRS 5164, Université Victor Segalen Bordeaux 2, Bordeaux, France
- Service de Médecine Interne, Hôpital Saint André, CHU de Bordeaux, Bordeaux, France
| | - Zachary Weitzner
- Department of Medicine-Renal Section, Boston University School of Medicine, Boston, Massachusetts, United States of America
| | - Christopher D. Andry
- Department of Medicine-Pathology, Boston University School of Medicine, Boston, Massachusetts, United States of America
| | - Ian R. Rifkin
- Department of Medicine-Renal Section, Boston University School of Medicine, Boston, Massachusetts, United States of America
| | - Tamar Aprahamian
- Department of Medicine-Renal Section, Boston University School of Medicine, Boston, Massachusetts, United States of America
- * E-mail:
| |
Collapse
|
6
|
Reed KL, Fruin AB, Gower AC, Gonzales KD, Stucchi AF, Andry CD, O'Brien M, Becker JM. NF-kappaB activation precedes increases in mRNA encoding neurokinin-1 receptor, proinflammatory cytokines, and adhesion molecules in dextran sulfate sodium-induced colitis in rats. Dig Dis Sci 2005; 50:2366-78. [PMID: 16416193 DOI: 10.1007/s10620-005-3066-y] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/30/2003] [Accepted: 03/12/2004] [Indexed: 12/13/2022]
Abstract
Nuclear factor kappa B (NF-kappa B) plays a key role in initiating inflammation associated with colitis. A systematic study was conducted in the rat DSS colitis model to determine the temporal relationship between NF-kappa B activation and expression of substance P (SP), neurokinin-1 receptor (NK-1R), proinflammatory cytokines, and adhesion molecules. Rats were given 5% DSS in their water and sacrificed daily for 6 days. Colon tissue was collected for assessment of histological changes, NF-kappa B activation, myeloperoxidase (MPO) activity, and expression of NK-1R, SP, TNFalpha, IL-1beta, VCAM-1, ICAM-1, E-selectin, CINC-1, MIP-1alpha, and iNOS. NF-kappa B activation increased, biphasically, on Day 1 and again on Days 4-6. The mRNA levels for ICAM-1, CINC-1, IL-1beta, TNFalpha, VCAM-1, and NK-1R rose significantly (P < 0.05) by 2-4 days. Increased iNOS mRNA levels, MPO activity, and mucosal damage occurred on Day 6. These data demonstrate that NF-kappa B activation substantially precedes the onset of physical disease signs and active inflammation.
Collapse
Affiliation(s)
- Karen L Reed
- Department of Surgery, Boston University School of Medicine, Boston, Massachusetts 02118, USA
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Stucchi AF, Shebani KO, Leeman SE, Wang CC, Reed KL, Fruin AB, Gower AC, McClung JP, Andry CD, O'Brien MJ, Pothoulakis C, Becker JM. A neurokinin 1 receptor antagonist reduces an ongoing ileal pouch inflammation and the response to a subsequent inflammatory stimulus. Am J Physiol Gastrointest Liver Physiol 2003; 285:G1259-67. [PMID: 12893626 DOI: 10.1152/ajpgi.00063.2003] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Ileal pouch-anal anastomosis (IPAA) is an excellent surgical option for patients with chronic ulcerative colitis (CUC) requiring colectomy; however, persistent episodes of ileal pouch inflammation, or pouchitis, may result in debilitating postoperative complications. Because considerable evidence implicates substance P (SP) as an inflammatory mediator of CUC, we investigated whether SP participates in the pathophysiology of pouchitis. With the use of a rat model of IPAA that we developed, we showed that ileal pouch MPO levels and neurokinin 1 receptor (NK-1R) protein expression by Western blot analysis were significantly elevated 28 days after IPAA surgery. In situ hybridization and immunohistochemistry showed that the increase in NK-1R protein expression was localized to the lamina propria and epithelia of pouch ileum. The intraperitoneal administration of the NK-1R antagonist (NK-1RA) CJ-12,255 for 4 days, starting on day 28, was effective in reducing MPO levels. Starting on day 28, animals with IPAA were given 5% dextran sulfate sodium (DSS) in their drinking water for 4 days, which caused histological and physical signs of clinical pouchitis concomitant with significant increases in ileal pouch MPO concentrations as well as NK-1R protein expression by Western blot analysis. In situ hybridization and immunohistochemistry showed that the increase in NK-1R protein expression was especially evident in crypt epithelia of pouch ileum. When the NK-1RA was administered 1 day before starting DSS and continued for the duration of DSS administration, the physical signs of clinical pouchitis and the rise in MPO were prevented. These data implicate SP in the pathophysiology of pouchitis and suggest that NK-1RA may be of therapeutic value in the management of clinical pouchitis.
Collapse
Affiliation(s)
- Arthur F Stucchi
- Department of Surgery, Boston University School of Medicine, Boston, Massachusetts 02118, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Ghellai AM, Stucchi AF, Chegini N, Ma C, Andry CD, Kaseta JM, Burns JW, Skinner KC, Becker JM. Role of transforming growth factor beta-1 in peritonitis-induced adhesions. J Gastrointest Surg 2000; 4:316-23. [PMID: 10769096 DOI: 10.1016/s1091-255x(00)80082-7] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Peritonitis is a major cause of intra-abdominal adhesion formation. The overexpression of transforming growth factor beta-1 (TGF-Beta1), a potent mitogen, chemoattractant, and stimulant for collagen synthesis by fibroblasts, has been linked to tissue fibrosis at various sites throughout the body including peritoneal adhesion formation. Hence we hypothesized that the mechanism(s) involved in peritonitis-induced adhesion formation may be mediated through the upregulation of TGF-Beta1 expression. Peritonitis was induced in rats by cecal ligation and puncture, while a control group underwent sham operation. Adhesions were scored and harvested from both groups at 0, 6 and 12 hours and at 1, 2, 4, 7, and 28 days. Tissue expression of TGF-Beta1 mRNA was determined by quantitative reverse transcription-polymerase chain reaction and TGF-Beta1 protein was localized by immunohistochemical analysis. Serum and peritoneal fluid TGF-Beta1 concentrations were quantified by enzyme-linked immunosorbent assay. Compared with sham operation, peritonitis was associated with a significantly greater incidence of abdominal adhesions and a significant increase in the levels of TGF-Beta1 mRNA expression at days 2, 4, and 7. Immunostaining intensity of TGF-Beta1 in adhesions from the peritonitis group also steadily rose through day 7. In peritoneal fluid, the ratio of active:total TGF-Beta1 was significantly increased in the peritonitis group on days 1, 2, and 4 compared with the sham group. These results suggest that peritonitis is associated with the upregulation of TGF-Beta1, a mechanism that may exacerbate adhesion formation.
Collapse
Affiliation(s)
- A M Ghellai
- Department of Surgery, Boston University School of Medicine, MA 02118, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
9
|
O'Keane JC, Kupchik HZ, Schroy PC, Andry CD, Collins E, O'Brien MJ. A three-dimensional system for long-term culture of human colorectal adenomas. Am J Pathol 1990; 137:1539-47. [PMID: 2260636 PMCID: PMC1877731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Studies of the adenoma-carcinoma sequence in the colon and rectum have been limited by the paucity of experimental models of adenoma growth and progression. Progress recently was reported in the development of monolayer culture systems. The principal objective of this study was to develop a primary culture system for colorectal adenomas that would simulate three-dimensional in vivo growth. We used a calcium alginate encapsulation technique that was previously described for established tumor cell lines. Briefly, fresh resected specimens were washed, minced into small multicellular particles called microadenomas, and encapsulated in 1% calcium alginate pellets. The pellets were maintained in minimum essential medium containing 10% fetal bovine serum at 37 degrees C in humidified atmosphere of 95% air, 5% CO2. Ten of eleven adenomas, including six tubular, three tubulovillous, and one villous have been successfully cultured for 34 to 162 days. Cell viability was confirmed histologically by light and electron microscopy. The cells were characterized as epithelial by morphologic features and ultrastructural studies, which showed a high degree of cellular differentiation, including villous brush borders and many desmosomes. Both tubular and villuslike structures have been observed in vitro, correlating in some cases with the histology of the parent adenoma. Measurements of proliferative activity by [3H]thymidine autoradiography or immunohistochemical staining with the monoclonal antibody Ki-67 demonstrated growth fractions of 9% to 25%. A simple, highly efficient primary culture system was developed for the long-term maintenance of adenomas that promotes three-dimensional growth patterns and growth rates analogous to those seen in vivo. This model provides an opportunity to develop an experimental system for longitudinal studies of pathologic and molecular parameters in adenoma progression to carcinoma.
Collapse
Affiliation(s)
- J C O'Keane
- Mallory Institute of Pathology, Boston, MA 02118
| | | | | | | | | | | |
Collapse
|
10
|
Andry CD, Kupchik HZ, Rogers AE. L-azaserine induced preneoplasia in the rat pancreas. A morphometric study of dietary manipulation (lipotrope deficiency) and ultrastructural differentiation. Toxicol Pathol 1990; 18:10-7. [PMID: 2362985 DOI: 10.1177/019262339001800102] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Putatively preneoplastic, pancreatic atypical acinar cell foci (AACF) and nodules (AACN), collectively termed atypical acinar cell lesions (AACL), were induced in male Lewis rats by L-azaserine (300 mg/kg body weight [bw] in divided doses). Rats given carcinogen and then fed a lipotrope deficient (LD) diet developed a significantly greater number of larger lesions than animals fed complete diet throughout the experiment. It is suggested that lipotrope deficiency plays a promoting role in this model of pancreatocarcinogenesis. Ultrastructural morphometric studies of AACF, when compared to control tissues, revealed the following significant results: 1) a decrease in surface area of cell cytoplasm with no change in nuclear area, and hence increased nucleus/cytoplasm (N/C) ratio; 2) a reduction in size and uniformity of zymogen granules; and 3) an increase in number of granules per microns 2 of cell. The results suggest that arrested development of the AACF cells is associated with reduced cytoplasm and zymogen production per cell. AACL may be eosinophilic due to an overall increased concentration of zymogen in these hyperplastic lesions and not because individual acinar cells in the AACL contain an increased amount of zymogen or are "zymogen-rich," as has been reported.
Collapse
Affiliation(s)
- C D Andry
- Mallory Institute of Pathology, Boston, Massachusetts 02118
| | | | | |
Collapse
|